Myovant Sciences Ltd. (MYOV)
(Delayed Data from NYSE)
$17.72 USD
+0.07 (0.40%)
Updated May 3, 2019 04:01 PM ET
After-Market: $17.69 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.72 USD
+0.07 (0.40%)
Updated May 3, 2019 04:01 PM ET
After-Market: $17.69 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Stock Jumps 16.3%: Will It Continue to Soar?
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Myovant Sciences (MYOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -69.23% and 8.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Myovant Sciences (MYOV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -14.55% and 5.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Myovant Sciences (MYOV) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Myovant Sciences (MYOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
by Zacks Equity Research
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.
Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -15.25% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Myovant Sciences (MYOV) Rating Upgrade to Buy
by Zacks Equity Research
Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 32.35% and 7.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA
by Zacks Equity Research
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Myovant Sciences (MYOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.
Here's Why Pfizer (PFE) Has Been Rallying This Year So Far
by Zacks Equity Research
Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.
Myovant Sciences (MYOV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 10.10% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
by Kinjel Shah
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
by Zacks Equity Research
Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
by Zacks Equity Research
Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.
Myovant Sciences (MYOV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 7.87% and 27.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
by Zacks Equity Research
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.